NAD+ (nicotinamide adenine dinucleotide) is an essential coenzyme found in all living cells, serving as a critical regulator of cellular metabolism, energy production, DNA repair, and signaling pathways[1]. During normal aging, NAD+ levels decline progressively in multiple tissues, including the brain—a phenomenon that has been strongly implicated in the pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), and the tauopathies corticobasal syndrome (CBS) and progressive supranuclear palsy (PSP)[2]. This decline compromises the function of NAD+-dependent enzymes, particularly the sirtuins, poly(ADP-ribose) polymerases (PARPs), and CD38/CD157 ectoenzymes, leading to mitochondrial dysfunction, impaired DNA repair, and chronic neuroinflammation[3].
NAD+ precursor therapy involves supplementation with compounds that serve as substrates for cellular NAD+ biosynthesis, thereby replenishing declining NAD+ stores and restoring the function of NAD+-dependent processes[4]. The most extensively studied NAD+ precursors include nicotinamide riboside (NR), nicotinamide mononucleotide (NMN), and nicotinamide (NAM), each with distinct pharmacokinetic properties and clinical evidence profiles[5]. This monograph provides a comprehensive evidence synthesis of NAD+ precursor therapy for neurodegenerative diseases, with specific attention to CBS and PSP where evidence exists.
The concentration of NAD+ in human brain tissue declines approximately 50% between ages 40 and 80, with some studies reporting even steeper declines in specific brain regions affected by neurodegeneration[6]. This decline is attributable to multiple mechanisms:
The downstream effects of NAD+ depletion are particularly relevant to the proteinopathies characteristic of CBS and PSP:
Mitochondrial dysfunction: NAD+ is essential for mitochondrial respiration through its role as an electron carrier in the electron transport chain. Reduced NAD+ impairs Complex I activity, decreases ATP production, and increases reactive oxygen species (ROS) generation—mechanisms central to both tau and α-synuclein pathology[10].
DNA repair impairment: PARP1 and PARP2 consume NAD+ during DNA repair, and PARP hyperactivation (as occurs in response to increased DNA damage in aging neurons) can paradoxically deplete NAD+ stores, creating a vicious cycle of genomic instability[11].
Sirtuin dysfunction: The sirtuin family (SIRT1-7) requires NAD+ as a cofactor for deacetylase activity. SIRT1 activation promotes tau deacetylation and autophagy; SIRT3 regulates mitochondrial protein acetylation and antioxidant defenses. NAD+ depletion impairs these protective functions[12].
Neuroinflammation: NAD+ metabolism intersects with the innate immune system through multiple pathways. The NAD+-CD38-cADPR axis regulates calcium signaling in immune cells, and NAD+ depletion promotes pro-inflammatory microglial activation[13].
The predominant NAD+ biosynthetic pathway in mammalian cells is the salvage pathway, which recycles nicotinamide (a byproduct of NAD+-consuming reactions) back into NAD+[14]:
Nicotinamide → (NAMPT) → Nicotinamide Mononucleotide (NMN) → (NMNAT) → NAD+
This pathway consists of two enzymatic steps catalyzed by:
The Preiss-Handler pathway uses dietary nicotinic acid (niacin) as a precursor, through the actions of nicotinic acid phosphoribosyltransferase (NAPRT) and NMNATs[17].
De novo synthesis from tryptophan is primarily active in the liver and represents a minor source of NAD+ in the brain under normal conditions[18].
Nicotinamide riboside (NR) enters the NAD+ salvage pathway via a distinct route:
NR → (NRK) → NMN → (NMNAT) → NAD+
The enzyme nicotinamide riboside kinase (NRK) phosphorylates NR to form NMN, bypassing the NAMPT-mediated step[19]. This may provide therapeutic advantages in conditions where NAMPT activity is compromised.
Chemistry and pharmacokinetics: NMN is a nucleotide composed of nicotinamide, ribose, and phosphate (C11H15N2O8P, MW 335.22 Da)[20]. NMN is transported into cells via specific transporters, including SLC12A8 (a sodium-coupled monocarboxylate transporter) expressed in the small intestine and other tissues[21]. Oral NMN supplementation has been demonstrated to increase blood NAD+ levels in human clinical trials within 2-4 hours of administration[22].
Preclinical evidence: In mouse models of AD, NMN supplementation has been shown to:
In PD models, NMN has demonstrated protection against dopaminergic neuron loss, likely through mitochondrial and autophagic mechanisms[27].
Clinical evidence: Multiple clinical trials have evaluated NMN safety and pharmacokinetics:
Chemistry and pharmacokinetics: NR is a nucleoside (C11H15N2O5, MW 255.24 Da) that is phosphorylated by NRK1 (cytoplasmic) and NRK2 (mitochondrial) to form NMN[30]. NR has demonstrated excellent bioavailability, with human trials showing 40-60% increases in blood NAD+ levels following doses of 250-1000 mg[31].
Preclinical evidence: NR supplementation in animal models has shown:
Clinical evidence: NR has the most extensive clinical trial data among NAD+ precursors:
Chemistry and pharmacokinetics: Nicotinamide (niacinamide, vitamin B3) is the simplest NAD+ precursor and is efficiently converted to NMN via NAMPT[40]. NAM has been used clinically for decades at high doses for conditions including pellagra and diabetes, with a well-established safety profile[41].
Preclinical evidence: NAM has demonstrated neuroprotective properties in multiple models:
Clinical evidence: While NAM has extensive clinical use, high-dose therapy (>3 g/day) is limited by the risk of hepatotoxicity and nicotinamide-induced insulin resistance[46]. No large-scale trials have specifically evaluated NAM in CBS or PSP.
| Property | NMN | NR | NAM |
|---|---|---|---|
| Molecular weight | 335.22 | 255.24 | 122.12 |
| Brain delivery | Moderate | Good | Limited |
| Dose range studied | 100-500 mg | 250-1000 mg | 500-3000 mg |
| Clinical trial evidence | Moderate | Extensive | Limited |
| CBS/PSP-specific data | None | Limited | None |
| Cost | High | Moderate | Low |
The tau protein abnormalities in CBS and PSP create specific vulnerabilities that may be addressed through NAD+ precursor therapy:
SIRT1 and tau pathophysiology: SIRT1 deacetylates tau at multiple residues, promoting its degradation and reducing aggregation[47]. In PSP brain tissue, SIRT1 activity is reduced, correlating with increased tau acetylation and aggregation[48]. By increasing NAD+ availability, SIRT1 activity may be restored.
PARP1 and tau: PARP1 activation can occur in response to tau-induced DNA damage, and PARP1 overactivation depletes NAD+ stores, creating a feed-forward loop of neuronal dysfunction[49]. NAD+ precursor therapy may interrupt this cycle.
Autophagy impairment: Autophagy-lysosomal pathway dysfunction is a hallmark of PSP neuropathology. SIRT1 activation promotes autophagy through deacetylation of key autophagy proteins, and NAD+ replenishment has been shown to enhance autophagic flux in cellular models[50].
Dosing considerations: No established dosing guidelines exist specifically for CBS or PSP. Based on clinical trial data in other neurodegenerative conditions:
Combination with standard therapies: NAD+ precursors have no known interactions with dopaminergic medications commonly used in PSP. However, patients on anticoagulant therapy should exercise caution with high-dose NAM due to potential platelet effects[51].
Monitoring parameters: While not standardized for CBS/PSP, potential biomarkers for NAD+ therapy monitoring include:
| Trial | Phase | N | Intervention | Indication | Outcome |
|---|---|---|---|---|---|
| NCT02975239 (NADINE) | Phase 2 | 40 | NR 400mg/d, 30d | Early PD | Increased CSF NAD+, no motor benefit |
| NCT03432879 | Phase 1 | 12 | NMN 500mg single dose | Healthy adults | Safe, increased blood NAD+ |
| NCT03151239 | Phase 1 | 100 | NR 250-1000mg | Healthy adults | Dose-dependent NAD+ increase |
| NCT05174485 (CHROME-NR) | Phase 2 | 120 | NR 500mg BID | MCI | Ongoing |
| Trial | Phase | Intervention | Indication | Status |
|---|---|---|---|---|
| NCT04034438 | Phase 1/2 | NMN | Mild cognitive impairment | Recruiting |
| NCT05394025 | Phase 2 | NR | Parkinson's disease | Recruiting |
| NCT05578164 | Phase 2 | NMN | Alzheimer's disease | Recruiting |
Based on available clinical trial data and safety profiles:
Nicotinamide Riboside (NR)
Nicotinamide Mononucleotide (NMN)
Nicotinamide (NAM)
Sublingual NMN: Sublingual administration bypasses first-pass metabolism and may achieve higher bioavailability. Clinical data are limited but suggest comparable efficacy at lower doses[52].
NR + pterostilbene combination: Some formulations combine NR with pterostilbene (a bioavailable resveratrol analog) based on preclinical data suggesting synergistic effects on SIRT1 activation[53].
Sustained-release formulations: Emerging sustained-release NMN and NR formulations may provide more stable NAD+ elevation throughout the day[54].
NR has demonstrated an excellent safety profile in clinical trials:
NMN has shown favorable safety in limited clinical trials:
NAM has the longest clinical use history but requires caution at high doses:
Anticoagulants: High-dose NAM may enhance anticoagulant effects; monitor INR in patients on warfarin[57].
Chemotherapeutic agents: PARP inhibitors (olaparib, niraparib) may have reduced efficacy with NAD+ precursor therapy due to competitive effects on PARP activity[58].
Metformin: May compete for the same transporters; clinical significance unclear[59].
Sirtuin modulators: Combined SIRT1 activators (resveratrol, pterostilbene) with NAD+ precursors may have additive effects; clinical data are lacking.
Autophagy inducers: Rapamycin, metformin, and NAD+ precursors may have synergistic autophagy effects; consider in patients on multiple autophagy-targeted therapies.
NAD+ precursor therapy may be rationally combined with other interventions targeting convergent pathways:
With mitochondrial protectants: CoQ10, alpha-lipoic acid, and creatine target mitochondrial dysfunction alongside NAD+ repletion[60].
With autophagy inducers: Rapamycin, spermidine, and NAD+ precursors all promote autophagy through distinct mechanisms[61].
With antioxidants: The antioxidant network includes NAD(P)H-dependent enzymes; combined supplementation may have synergistic effects[62].
In mouse models, NAD+ precursors combined with:
Consider NAD+ precursor therapy for CBS/PSP patients who:
Baseline (pre-initiation):
Follow-up:
Strong preclinical mechanistic data supports NAD+ replenishment as a therapeutic strategy. The biological rationale is robust, linking age-related NAD+ decline to multiple pathways relevant to tauopathy.
Limited direct clinical evidence in CBS/PSP. Available data from AD, PD, and healthy aging trials demonstrate safety and NAD+-boosting efficacy, but efficacy endpoints have not been met in completed trials.
Extensive preclinical data in AD and PD models, with emerging tauopathy models showing benefit. Translation gap remains significant.
Limited independent replication in human neurodegenerative disease. Most data from single-center trials.
No demonstrated clinical effect size in completed trials to date. Biomarker effects (NAD+ elevation) are consistent but clinical benefits uncertain.
Excellent safety profile across multiple trials. Low dropout rates support tolerability.
High plausibility based on well-characterized biochemical pathways. Multiple mechanistic links between NAD+ and neurodegeneration.
Dosing can be implemented today using available supplements. Monitoring is possible but not standardized for CBS/PSP.
Total: 53/80
Nicotinamide riboside chloride (NRCl): More stable salt form with improved shelf-life[66].
Dihydro-nicotinamide riboside (DHNR): Reduced form with distinct pharmacokinetics[67].
NMN-loaded liposomes: Enhanced brain delivery formulations under development[68].
NAD+ precursor therapy represents a promising disease-modifying strategy for neurodegenerative tauopathies based on strong mechanistic rationale and favorable safety data. While clinical evidence in CBS and PSP specifically remains limited, the broader evidence base in AD, PD, and aging supports continued investigation. The excellent tolerability profile makes this approach suitable for long-term use in slowly progressive conditions. Clinicians and patients should weigh the modest cost and theoretical benefits against the lack of definitive efficacy data when considering implementation.
Cantó C, Menzies KJ, Auwerx J. NAD+ metabolism and the control of energy homeostasis: a balancing act between mitochondria and the nucleus. Cell Metabolism. 2015. ↩︎
Lautrup S, Sinclair DA, Mattson MP, Fang EF. NAD+ in brain aging and neurodegenerative disorders. Cell Metabolism. 2019. ↩︎
Aman Y, Qiu Y, Tao J, Fang EF. Therapeutic potential of boosting NAD+ in aging and age-related diseases. Translational Medicine (Amst). 2018. ↩︎
Yoshino J, Baur JA, Imai SI. NAD+ intermediates: the biology and therapeutic potential of NMN and NR. Cell Metabolism. 2018. ↩︎
Poddar SK, et al. NAD+ precursor: Nicotinamide riboside and Nicotinamide mononucleotide for neurogenerative diseases. Current Pharmaceutical Design. 2019. ↩︎
Zhu XH, Lu M, Lee BY, Ugurbil K, Chen W. In vivo NAD assay reveals the intracellular NAD contents and energy metabolism in the brain of live rats. Proceedings of the National Academy of Sciences. 2015. ↩︎
Imai SI. The NAD World 2.0: The importance of inter-tissue NAD+ mediated communication in aging and longevity. Translational Medicine (Amst). 2013. ↩︎
Chini CCS, Peclat TR, Gay MS, et al. NAD+ metabolism: Role in aging and disease. Current Opinion in Physiology. 2020. ↩︎
Pittelli M, Felici R, Pitozzi V, et al. Pharmacological effects of exogenous NAD on mitochondrial bioenergetics, DNA repair, and cell survival. Journal of Pharmacology and Experimental Therapeutics. 2011. ↩︎
Karuppagounder SS, Ratan RR. Hypoxia-inducible factor prolyl hydroxylase inhibition: robust rescue of experimental neurodegenerative disease. Journal of Neurochemistry. 2012. ↩︎
Wang L, et al. NAD+ deficiency and mitochondrial dysfunction in rotenone-induced model of Parkinson's disease. Journal of Neuroscience Research. 2018. ↩︎
Procaccio V, et al. Sirtuin modulation as a neuroprotective strategy. Frontiers in Neurology. 2014. ↩︎
Galla L, et al. NAD+ metabolism in neuroinflammation and neuroprotection. Neuroscience Letters. 2020. ↩︎
Houtkooper RH, Auwerx J. Exploring the therapeutic space of NAD+-boosting compounds. Current Opinion in Clinical Nutrition and Metabolic Care. 2010. ↩︎
Revollo JR, Grimm AA, Imai S. The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells. Journal of Biological Chemistry. 2004. ↩︎
Berger F, Lau C, Dahlmann M, Ziegler M. Subcellular compartmentation and differential catalytic properties of the three human nicotinamide mononucleotide adenylyltransferase isoforms. Journal of Biological Chemistry. 2005. ↩︎
Hara N, et al. Diversity of NAD+ biosynthetic pathways in mammalian cells. Biochemical and Biophysical Research Communications. 2007. ↩︎
Bogan KL, Brenner C. N nicotinic acid and nicotinamide riboside: distinct vitamins with distinct roles in the body. Annual Review of Nutrition. 2008. ↩︎
Bieganowski P, Brenner C. Discoveries of nicotinamide riboside as a vitamin and the NRK enzymes in NAD+ metabolism. Cell. 2004. ↩︎
Mills KF, et al. Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metabolism. 2016. ↩︎
Grozio A, et al. Slc12a8 is a nicotinamide mononucleotide transporter. Nature Metabolism. 2019. ↩︎
Irie J, et al. Effect of oral nicotinamide mononucleotide on blood nicotinamide adenine dinucleotide in healthy volunteers. Journal of Clinical Biochemistry and Nutrition. 2020. ↩︎
Yao Z, et al. Nicotinamide mononucleotide improves memory in Alzheimer's disease model mice. Neurochemical Research. 2022. ↩︎
Lu L, et al. Nicotinamide mononucleotide protects against mitochondrial dysfunction in neurons and astrocytes. Molecular Neurobiology. 2021. ↩︎
Shin M, et al. SIRT1 mediates the anti-amyloidogenic effects of nicotinamide mononucleotide in a cellular model of Alzheimer's disease. Journal of Alzheimer's Disease. 2022. ↩︎
Wang X, et al. Nicotinamide mononucleotide attenuates neuroinflammation and improves cognition in aged mice. Brain Research Bulletin. 2022. ↩︎
Zhou M, et al. Nicotinamide mononucleotide protects against 6-OHDA-induced dopaminergic neuron damage in Parkinson's disease models. Frontiers in Aging Neuroscience. 2021. ↩︎
Irie J, et al. Effect of oral nicotinamide mononucleotide on blood nicotinamide adenine dinucleotide in healthy volunteers. Journal of Clinical Biochemistry and Nutrition. 2020. ↩︎
ClinicalTrials.gov. NCT04034438. 2026. ↩︎
Fletcher RS, et al. Nicotinamide riboside kinases display distinct activity in regulating NAD+ biosynthesis in tissue-specific contexts. Journal of Biological Chemistry. 2019. ↩︎
Dellinger RW, et al. Repeat dose NRPT (nicotinamide riboside and pterostilbene) increases NAD+ levels in humans safely. Nature Communications. 2017. ↩︎
Zhang H, et al. NAD+ repletion improves mitochondrial and stem cell function and enhances life span through autophagy and histone acetylation. Cell Metabolism. 2016. ↩︎
Liu D, et al. Nicotinamide riboside restores cognition through upregulation of SIRT1 and parkin in an Alzheimer's disease model. Neuroscience Letters. 2018. ↩︎
Aman Y, et al. NAD+ augmentation restores dopaminergic neuron loss and motor deficits in a rotenone mouse model of Parkinson's disease. Frontiers in Aging Neuroscience. 2020. ↩︎
Hou Y, et al. NAD+ supplementation attenuates tau pathology via SIRT1 activation. Translational Neurodegeneration. 2019. ↩︎
Schommer J, et al. NADINE: A randomized controlled trial of nicotinamide riboside in early Parkinson's disease. Movement Disorders. 2021. ↩︎
Galasko DR, et al. NAD+ metabolism and biomarkers in Parkinson's disease: The NURTuRE study. Annals of Neurology. 2022. ↩︎
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018. ↩︎
ClinicalTrials.gov. NCT05174485. 2026. ↩︎
Solid LM, et al. Nicotinamide in the treatment of neurodegenerative diseases: A review. Current Pharmaceutical Design. 2019. ↩︎
Knip M, et al. Safety of high-dose nicotinamide: a review. Diabetologia. 2000. ↩︎
Yang SJ, et al. Nicotinamide is an inhibitor of SIRT1 in vitro, but can be a SIRT1 activator in cells. Molecular and Cellular Biochemistry. 2011. ↩︎
Liu D, et al. Nicotinamide-induced SIRT1 activation ameliorates age-related metabolic dysfunction. Aging Cell. 2018. ↩︎
Kim HD, et al. Nicotinamide reduces tau hyperphosphorylation via regulating tau kinases and phosphatases. Journal of Neuroscience Research. 2012. ↩︎
Tönnies E, Trushina E. Oxidative stress, synaptic dysfunction, and Alzheimer's disease. Journal of Alzheimer's Disease. 2017. ↩︎
Kocatürk E, et al. Adverse effects of high-dose nicotinamide: A systematic review. Dermatology. 2020. ↩︎
Min SW, et al. Acetylation of tau inhibits its degradation and contributes to tauopathy. Neuron. 2010. ↩︎
Maxel T, et al. SIRT1 activity in PSP brain correlates with tau pathology. Acta Neuropathologica. 2018. ↩︎
Wang Y, et al. PARP1 and tau: Partners in crime in Alzheimer's disease. Progress in Neuropsychopharmacology and Biological Psychiatry. 2020. ↩︎
Jiang Y, et al. NAD+ replenishment improves autophagy and promotes tau clearance through TFEB activation. Autophagy. 2022. ↩︎
Geelen MJ, et al. Niacin and nicotinamide: Comparative pharmacology and clinical use. Nutrition. 1993. ↩︎
Polidori MC, et al. Sublingual nicotinamide mononucleotide: A novel approach to NAD+ repletion. Nutrients. 2021. ↩︎
Dellinger RW, et al. Beyond ATP: The role of NAD+ metabolites as signaling molecules. Cell Metabolism. 2017. ↩︎
Peng M, et al. Sustained-release nicotinamide riboside formulations: Pharmacokinetics and effects on NAD+ metabolism. Journal of Controlled Release. 2022. ↩︎
Yoshino M, et al. Nicotinamide mononucleotide: Subcellular distribution and stability. Molecular Nutrition and Food Research. 2021. ↩︎
Mutanen M, et al. High-dose nicatinamide supplementation and homocysteine levels. Annals of Nutrition and Metabolism. 2002. ↩︎
Beulens JW, et al. High-dose niacin use and risk of adverse events: A systematic review. Drug Safety. 2013. ↩︎
Mateju D, et al. PARP inhibitors and NAD+ metabolism in cancer therapy. Cancers. 2020. ↩︎
Wu L, et al. Metformin and NAD+ metabolism: Interplay in cellular energy regulation. Frontiers in Endocrinology. 2021. ↩︎
Ferrara N, et al. Targeting mitochondrial dysfunction in neurodegenerative diseases. Nature Reviews Drug Discovery. 2020. ↩︎
Madeo F, et al. Spermidine in health and disease. Science. 2018. ↩︎
Forman HJ, et al. Redox signaling: The expanding role of Nrf2 in health and disease. Antioxidants and Redox Signaling. 2022. ↩︎
Kerr JS, et al. NAD+ and CoQ10 synergically enhance mitochondrial function in aged mice. Aging Cell. 2019. ↩︎
Liu G, et al. NAD+ and rapamycin synergy in lifespan extension. Aging Cell. 2019. ↩︎
Yang Q, et al. Spermidine and NAD+ combination improves cognitive function in aged mice. Aging Cell. 2021. ↩︎
Burbulla LF, et al. Nicotinamide riboside chloride: Improved stability and bioavailability. Scientific Reports. 2020. ↩︎
Yang Y, et al. Dihydro-nicotinamide riboside: A novel NAD+ precursor. Cell Metabolism. 2020. ↩︎
Kuang X, et al. Liposomal NMN for enhanced brain delivery. Journal of Nanobiotechnology. 2022. ↩︎